

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Francesco PARENTI	)	Group Art Unit: 1653
	)	
U.S. Patent No.: 6,720,305	)	Examiner: David LUKTON
	)	
Issued: April 13, 2004	)	Confirmation No.: 4708
	)	
For: INJECTABLE FORMULATIONS	)	
CONTAINING RAMOPLANIN	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REVOCATION OF POWER OF ATTORNEY  
STATEMENT UNDER 37 C.F.R. § 3.73(b)  
AND GRANT OF NEW POWER OF ATTORNEY**


The undersigned, a representative authorized to sign on behalf of Assignee, Nanotherapeutics, Inc., hereby revokes all previous powers of attorney or authorization of agent granted in this patent before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that Nanotherapeutics, Inc. is the Assignee of the entire right, title, and interest in the patent identified above by virtue of an assignment from Oscient Pharmaceuticals Corporation to Nanotherapeutics, Inc. recorded for this patent on December 18, 2009, at Reel 023668, Frame 0852.

The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Customer Number 22,852**, to transact all business in the Patent and Trademark Office connected with this patent.

Please send all future correspondence concerning this patent to Finnegan,  
Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Dated: 2/9/10

By:   
Name: James D. Talton, Ph.D.  
Title: President & CEO  
Nanotherapeutics, Inc.

533006v1